OBSV - ObsEva presents data from Phase 2a PROLONG study in spontaneous preterm labor at RCOG 2021

ObsEva (OBSV) presents clinical data from the PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for the treatment of spontaneous preterm labor at the RCOG Virtual World Congress 2021.As previously disclosed in November 2020, the PROLONG data demonstrated that ebopiprant was well tolerated and showed early evidence of efficacy in pregnant women with spontaneous preterm labor and supports the advancement into a Phase 2b/3 adaptive study. “Preparations are ongoing to initiate a Phase 2b/3 clinical study in Q4:21. We believe this adaptive study has the potential to support an accelerated registration program in Europe, and we look forward to providing additional updates on our progress later this year," said Brian O’Callaghan, CEO."We also plan to engage the FDA in discussions regarding the US clinical program for ebopiprant," he added.

For further details see:

ObsEva presents data from Phase 2a PROLONG study in spontaneous preterm labor at RCOG 2021